CEO Founder = allocating time between recruiting: Talent Customers Capital Best skill for achieving all of the above efficiently? Great story telling.

This is really big news. Google introduced the Open Knowledge Format (OKF) - a standardized way to store information in a directory of markdown files. Makes it really easy to make a digital brain that agents can use. These files can serve as a living wiki. You can give agents the ability to query them or edit them. They can interlink. Seems to me this could replace Notion or Obsidian. I can think of so many uses for this. Google's blog post: cloud.google.com/blog/produc… An easier to understand explanation is the SPEC.md file: github.com/GoogleCloudPlatfo… I gave those two links to Antigravity and asked how we could use it for any of the projects we're working on. It came up with so many ideas. I would imagine Claude Fable 5 would whip up some pretty amazing things based on this system. Currently creating an OKF library of our pepper garden. It's going to be a fun weekend.

Seeing a lot of bitter lesson/scale > specialized model tweets about this study, but short of OE/UTD intentionally buying weaker models, this result is more of a *harness* issue than a model one. MedQA score ranges across models were within 9 points (so less likely a base knowledge gap); the gap between gen vs clinical models widened on the real world clinical question answers, where the problems were mostly in omission and disorganized outputs rather than wrong facts.

Recession bites in Vancouver as Chanel queues down to 20 minutes..

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

One of my personal favorite features announced at WWDC will I suspect be a sleeper hit: container machines, allowing your Mac to run a lightweight, persistent Linux environment with your home directory and repos automatically mounted: github.com/apple/container/b…

Here’s your monthly reminder that you shouldn’t be prompting coding agents anymore. You should be designing loops that prompt your agents.

Introducing a research system that enables passive heart rate monitoring (PHRM) during everyday smartphone use. Using the front-facing camera, it achieves industry accuracy standards for heart rate across all skin tones. Check out the blog to learn more: goo.gle/4dQTc2B

Welp, that happened faster than I predicted. Thought it would be end of 2027, then early 2027, but agentic traffic growing so fast that bots have now passed human traffic online for the first time in the Internet's history. radar.cloudflare.com/traffic…

Unfiltered coffee raises your LDL cholesterol. Filtered coffee does not. The bean is identical. The only thing that changes is whether the brew passes through paper. Coffee oil carries two diterpenes, cafestol and kahweol. They survive in French press, espresso, boiled, and Turkish coffee, and a paper filter traps almost all of them. That single step is the difference. Once in your body, the diterpenes lead the liver to clear less cholesterol from your blood, and LDL climbs. Cafestol is one of the most potent cholesterol-raising compounds in the diet, and the effect shows up in controlled human trials, not just observational data. The diterpenes nudge triglycerides up too. How much you get depends almost entirely on the brewing method. Per cup: Unfiltered or boiled: about 4.4 mg French press: about 2.8 mg Espresso: about 1.2 mg Paper-filtered drip: about 0.08 mg That is roughly a 55-fold difference between an unfiltered cup and a paper-filtered one of the same coffee. The long-term data points the same way. In 508,747 Norwegians followed for about 20 years, filtered coffee drinkers had lower mortality than people who drank no coffee at all. Unfiltered drinkers saw little or none of that benefit, and in men over 60, heavy unfiltered intake was associated with higher cardiovascular death. The risk tracked cholesterol: it grew when cholesterol was removed from the statistical model. One honest caveat. That the LDL rise happens is well established. The exact molecular step, how the diterpenes lower cholesterol clearance, is still being worked out. If your LDL is a concern, this is one of the easiest levers you have. You do not have to give up coffee. You just have to run it through paper. Naidoo et al., Nutr J, 2011 Urgert et al., Eur J Clin Nutr, 1995 de Roos et al., J Intern Med, 2000 Tverdal et al., Eur J Prev Cardiol, 2020

This has quietly been a miracle month in medicine. In the last 5 weeks we’ve got news on: - retatrutide, the triple agonist GLP-1 from Lilly, basically melting fat and body-wide inflammation at record levels - RevMed’s new pancreatic cancer drug showing unprecedented abilities to extend life - small trial of a one-and-done PCSK9 gene editing therapy for slashing LDL cholesterol - Mayo’s AI-assisted radiology showing vastly improved cancer detection - this new therapy for metastatic solid tumors This stuff is at varying levels of evidence. Retatrutide is ~100% on its way, other stuff needs more clinical trial data. But put it together and we’re maybe on the verge of majorly reducing the mortality of heart disease and cancer, the two leading causes of death in America.

Men who can't squeeze 70 lbs of grip by 60 have 3x the all-cause mortality risk of men who can squeeze 100 . Not 30% higher. Three times. Grip strength is the cheapest, most predictive longevity marker in medicine. Better than VO2 max. Better than BMI.

What do Harvard, Oxford, Stanford, Univ of Edinburgh, Mayo Clinic, Ohio State, James Cook, UCSF, and UCSD share in common? They are all conducting trials of ketogenic diets for mental illness. The results could change the field of psychiatry.

You don't have to inject forever. New trial: people who lost 22% on tirzepatide injections switched to a once-daily ORAL GLP-1 (orforglipron). 52 weeks later they kept ~75% of the weight off. Same story for semaglutide → oral: ~80% maintained. The pill era of GLP-1s is starting: 🧵

If this is true, using the best public estimates we have of LLM resource use, solving this Erdos problem took 0.6–6.3 kWh of electricity and about 3–31 liters of water. So that is less than three almonds worth of water and the electricity equivalent of 2-20 miles of EV driving.

The new Readwise MCP server is now out of beta. Search across every word in your library. Triage your inbox. Organize your data. Anything you can do in Readwise, your AI can now do for you. Connect from ChatGPT, Claude, Codex, Perplexity, Poke, or any other AI app.

In some very real sense, Ozempic was invented in 1990. Pfizer ran the human trials and just never published them. They showed it lowered blood glucose in diabetics, slowed gastric emptying, and killed hunger; the same 3 things that make Ozempic work today. The joint venture agreement said internal data stayed internal, and that was that. Pfizer killed the program in 1991. The reasoning, as far as I can tell, was that nobody would ever want an injectable diabetes drug besides insulin. So, the license went back to the hospital in Boston that held the patents. Novo picked it up in 1992 and spent the next two decades building liraglutide, then semaglutide. It's insane that data sat in a filing cabinet for 30 years. I only know this because Jeffrey Flier, one of the Harvard scientists in the room, finally wrote it up. He's in his late 70s and didn't want the history to die with him. This makes you wonder what else is in those filing cabinets. Ozempic could've existed 27 years ago.

I’ve had very good results running autoresearch with local qwen 3.6 26b model as long as I had a simple vibed pi “advisor” extension that allowed it to periodically ask GPT 5.5 for ideas. I think this direction has a lot of merit.

You vibecoded a website somewhere other than Replit? That’s not wise, but okay… we’re going to let you import it and get a free mobile app. Yes, FREE MOBILE APP!

People at major AI labs (using internal models) 3-4 months ahead of startup silicon valley engineers SV founders/eng 3-6 months ahead of NY NY founders/eng 6-12 months ahead of rest of world Most people have no idea how fast AI shifting as 1-2 years behind SOTA "The future is here, just not equally distributed" - Robert Heinlein